PALO ALTO, Calif. — Curio Bioscience today announced the commercialization of the world’s first technology that spatially contextualizes single-cell sequencing data, leveraging a breakthrough invention called Slide-tags developed by the Broad Institute of MIT and Harvard and published in Nature this past December. The first stage of Curio’s commercialization of...
Latest News
DAEJEON, South Korea — Curocell, South Korea based CAR-T specialized company (CEO: Gunsoo Kim), has completed Phase 2 clinical trial for its next-generation CD19 CAR-T therapy “Anbal-cel” that targets relapsed or refractory DLBCL (Diffuse Large B-cell Lymphoma). This announcement is a significant milestone and is paving the way towards the launch...
Cambridge, UK – Whole genome sequencing has improved clinical care of some children with cancer in England by informing individual patient care. New research from the Wellcome Sanger Institute, Cambridge University Hospitals NHS Trust, Great Ormond Street Hospital, and the University of Cambridge, supports the efforts to provide genome sequencing...
Toulouse, France – CVasThera, a biopharmaceutical company that specializes in the development of novel therapies for cardiovascular and bowel pathologies, today announces it has secured €1.3 million ($1.6M) in financial backing in its first funding round. These funds will triple the company’s equity and capital. It will enable CVasThera to...
On Tuesday, students at Cottonwood Elementary School (CWE) recognized Rare Disease Day, a day is hosted on the last day of February. The day aims to raise awareness for rare diseases and improve access to treatment and medical representation for individuals that have rare diseases. Cottonwood’s Mrs. Sitterud visited each...
BOSTON, Mass. — Cycle Pharmaceuticals Limited (Cycle) announces the launch of ORMALVI (dichlorphenamide) tablets, as a treatment option for patients with hyperkalemic periodic paralysis (HyperPP), hypokalemic periodic paralysis (HypoPP) and related variants, after the approval by the US Food and Drug Administration (FDA).1 PPP is thought to affect about 5,000...
BOSTON & CAMBRIDGE, England — Cycle Pharmaceuticals announced that the FDA has approved HARLIKU (nitisinone) Tablets for the reduction of urine homogentisic acid (HGA) in adult patients with AKU.1 Launching in July 2025, HARLIKU will be the first and only FDA-approved treatment for AKU,1 an ultra-rare genetic metabolic disorder in which...
GAINESVILLE, Fla. — Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding Cyclo...
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has posted its protocol on www.ClinicalTrials.gov and is preparing to commence its pivotal Phase 3...
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced that the last patient completed their last visit in the Phase 1/2 study evaluating Trappsol® Cyclo™,...